复宏汉霖(02696.HK)HLX04-O治疗黄斑变性3期临床研究达主要研究终点

阿斯达克财经
02 Apr

复宏汉霖(02696.HK) 公布,近日,重组抗VEGF人源化单克隆抗体注射液HLX04-O在一项于湿性年龄相关性黄斑变性中国患者中开展的3期临床研究达到主要研究终点。结果显示,HLX04-O组第48周最佳矫正视力较基线改善的平均字母数变化结果非劣于雷珠单抗组。

HLX04-O是在公司自主研发的汉贝泰的基础上开发的新的眼科制剂产品。2020年10月,公司将汉贝泰于全球范围眼科治疗用途和/或疗法的独家权利许可给亿胜生物科技(01061.HK) ,双方并约定共同开发相关产品。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-02 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10